Castle Biosciences, Inc.

Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information to make more accurate treatment plan decisions. From its beginnings in 2008, Castle Biosciences has consistently applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate and can be improved by incorporating personalized genomic information. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed. DecisionDx-Melanoma predicts risk of recurrence or metastasis for patients with invasive cutaneous melanoma, a deadly skin cancer. DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. We have development programs for other underserved skin cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma.Castle Biosciences is based in Friendswood, Texas and has laboratory operations in Phoenix, Arizona. For more information, please visit www.CastleBiosciences.com.